About: Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19)
Creator	Drosten, Christian Hippenstiel, Stefan Hocke, Andreas Suttorp, Norbert Corman, Victor Holger Müller-Redetzky, · Leif, · Sander, Erik Spies, Claudia Witzenrath, · Angermair, Stefan Bastian Opitz, · Burkert, · Dang-Heine, Chantip Eckardt, Kai-Uwe Endres, Matthias Frank, · Heim, M Hummel, Michael Hübner, Ralf Katrin, · Knauss, Samuel Krannich, · Kretzler, · Kurth, Florian Landmesser, Ulf Mall, Marcus Mittermaier, Mirja Mockenhaupt, P Roennefarth, Maria Rose, Matthias Ruwwe-Glösenkamp, Christoph Röhmel, Jobst Schmidt, Sein Schürmann, · Siegmund, Britta Spranger, Joachim Stegemann, Miriam Steffen, · Tacke, · Thibeault, Charlotte Treskatsch, Sascha Uhrig, · Von Kalle, Christof Zvorc, Saskia Zoller, ·
Source	Medline; PMC
abstract	PURPOSE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide causing a global health emergency. Pa-COVID-19 aims to provide comprehensive data on clinical course, pathophysiology, immunology and outcome of COVID-19, to identify prognostic biomarkers, clinical scores, and therapeutic targets for improved clinical management and preventive interventions. METHODS: Pa-COVID-19 is a prospective observational cohort study of patients with confirmed SARS-CoV-2 infection treated at Charité - Universitätsmedizin Berlin. We collect data on epidemiology, demography, medical history, symptoms, clinical course, and pathogen testing and treatment. Systematic, serial blood sampling will allow deep molecular and immunological phenotyping, transcriptomic profiling, and comprehensive biobanking. Longitudinal data and sample collection during hospitalization will be supplemented by long-term follow-up. RESULTS: Outcome measures include the WHO clinical ordinal scale on day 15 and clinical, functional, and health-related quality-of-life assessments at discharge and during follow-up. We developed a scalable dataset to (i) suit national standards of care, (ii) facilitate comprehensive data collection in medical care facilities with varying resources, and (iii) allow for rapid implementation of interventional trials based on the standardized study design and data collection. We propose this scalable protocol as blueprint for harmonized data collection and deep phenotyping in COVID-19 in Germany. CONCLUSION: We established a basic platform for harmonized, scalable data collection, pathophysiological analysis, and deep phenotyping of COVID-19, which enables rapid generation of evidence for improved medical care and identification of candidate therapeutic and preventive strategies. The electronic database accredited for interventional trials allows fast trial implementation for candidate therapeutic agents. TRIAL REGISTRATION: Registered at the German registry for clinical studies (DRKS00021688) ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s15010-020-01464-x) contains supplementary material, which is available to authorized users.
has issue date	2020-06-13(xsd:dateTime)
bibo:doi	10.1007/s15010-020-01464-x
bibo:pmid	32535877
has license	cc-by
sha1sum (hex)	85d8bf1e80a7ed9a48336849fb764b52d6d48bed
schema:url	https://doi.org/10.1007/s15010-020-01464-x
resource representing a document's title	Studying the pathophysiology of coronavirus disease 2019: a protocol for the Berlin prospective COVID-19 patient cohort (Pa-COVID-19)
has PubMed Central identifier	PMC7293426
has PubMed identifier	32535877
schema:publication	Infection
resource representing a document's body	covid:85d8bf1e80a7ed9a48336849fb764b52d6d48bed#body_text
is schema:about of	named entity 'pathophysiological' named entity 'identification' named entity 'Registered' named entity 'enables' named entity 'profiling' named entity 'scores' named entity 'Systematic' named entity 'Germany' covid:arg/85d8bf1e80a7ed9a48336849fb764b52d6d48bed named entity 'pathogen' named entity 'standards' named entity 'harmonized' named entity 'therapeutic' named entity 'Charité' named entity 'COVID-19' named entity 'assessments' named entity 'deep' named entity 'strategies' named entity 'Longitudinal data' named entity 'German' named entity 'data collection' named entity 'suit' named entity 'confirmed' named entity 'platform' named entity 'scalable' named entity 'data collection' named entity 'phenotyping' named entity 'follow-up' named entity 'therapeutic targets' named entity 'Charité' named entity 'therapeutic agents' named entity 'infection' named entity 'phenotyping' named entity 'cohort study' named entity 'standards of care' named entity 'WHO'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software